NCT05154994 2026-01-27
RESOLVE
University of Utah
Phase 1 Active not recruiting
Clinical Trials
12 trialsNCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04315233 2025-04-22
CHARGE
University of Utah
Phase 1 Recruiting
NCT04703920 2025-01-23
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02137759 2023-05-06
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Emory University
Phase 2 Unknown
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn
NCT01188707 2020-10-19
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Herlev Hospital
Phase 1/2 Terminated
NCT01686165 2018-08-28
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
Phase 2 Completed
NCT01090830 2018-02-23
HCH003
Holy Cross Hospital, Florida
Phase 1/2 Terminated
NCT02875002 2017-12-22
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Yale University
Phase 1 Withdrawn
NCT02701673 2016-05-04
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01075425 2016-04-15
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Phase 1 Completed